Patents by Inventor Stephen Locarnini
Stephen Locarnini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240150412Abstract: Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).Type: ApplicationFiled: August 21, 2023Publication date: May 9, 2024Applicants: CLEARB THERAPEUTICS LTD., MELBOURNE HEALTHInventors: Renae Walsh, Stephen Locarnini, Hans Netter, Ronald Farquhar
-
Patent number: 11773141Abstract: Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).Type: GrantFiled: May 9, 2019Date of Patent: October 3, 2023Assignees: CLEARB THERAPEUTICS LTD., MELBOURNE HEALTHInventors: Renae Walsh, Stephen Locarnini, Hans Netter, Ronald Farquhar
-
Publication number: 20220002349Abstract: Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).Type: ApplicationFiled: May 9, 2019Publication date: January 6, 2022Inventors: Renae Walsh, Stephen Locarnini, Hans Netter, Ronald Farquhar
-
Patent number: 9701982Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: February 5, 2013Date of Patent: July 11, 2017Assignee: ABL SAInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
-
Patent number: 9682109Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: October 20, 2006Date of Patent: June 20, 2017Assignee: ABL SAInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Peter William Angus
-
Publication number: 20160032410Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.Type: ApplicationFiled: October 14, 2014Publication date: February 4, 2016Inventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayre, Lilly Ka Wai Yuen, Peter William Angus, Joseph John Sasadeusz, Paul Desmond, Hans Tillman Leipzig, Thomas Bock Tuebingen, William Sievert, Sharon Lewin
-
Patent number: 8859198Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.Type: GrantFiled: June 4, 2007Date of Patent: October 14, 2014Assignee: ABL SAInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayre, Lilly Ka Wai Yuen, Peter William Angus, Joseph John Sasadeusz, Paul Desmond, Hans Tillman, Thomas Bock, William Sievert, Sharon Lewin
-
Publication number: 20140199268Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: ApplicationFiled: February 5, 2013Publication date: July 17, 2014Applicant: ABL SAInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
-
Publication number: 20130171620Abstract: The present invention relates generally to viral variants exhibiting reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic agents.Type: ApplicationFiled: July 12, 2012Publication date: July 4, 2013Applicant: MELBOURNE HEALTHInventors: Stephen A. LOCARNINI, Angeline I. Bartholomguez, Thein T. Aye, Robert A. de Man
-
Patent number: 8273527Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants.Type: GrantFiled: October 5, 2007Date of Patent: September 25, 2012Assignee: Melbourne HealthInventors: Angeline Bartholomeusz, Margaret Littlejohn, Anna Ayres, Stephen Locarnini
-
Patent number: 8211443Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: April 4, 2006Date of Patent: July 3, 2012Assignees: Melbourne Health, Austin Health, Southern HealthInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
-
Patent number: 7887813Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: October 31, 2007Date of Patent: February 15, 2011Assignees: Melbourne Health, St. Vincent's Hospital Melbourne, Austin HealthInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
-
Publication number: 20100203506Abstract: The present invention relates generally to viral variants exhibiting reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic agents.Type: ApplicationFiled: May 9, 2008Publication date: August 12, 2010Applicant: MELBOURNE HEALTHInventors: Stephen A. Locarnini, Angeline I. Bartholomeusz, Thein T. Aye, Robert A. de Man
-
Publication number: 20100075299Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.Type: ApplicationFiled: June 4, 2007Publication date: March 25, 2010Applicants: MELBOURNE HEALTH, AUSTIN HEALTH, BAYSIDE HEALTH, ST.VINCENT'S HOSPITAL (MELBOURNE) LTD. TRADING AS ST. VINCENT'S HOSPITAL MELBOURNE, SOUTHERN HEALTHInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayre, Lilly Ka Wai Yuen, Peter William Angus, Joseph John Sasadeusz, Paul Desmond, Hans Tillman, Thomas Bock, William Sievert, Sharon Lewin
-
Publication number: 20100003262Abstract: The present invention provides regulation of expression of toll-like receptors by the hepatitis B (HBV) pre-core protein, or its extracellular expression product the hepatitis B E antigen (HbeAg). Compounds regulating such expression have use in the treatment and prophylaxis of HBV infection in animal. The invention also provides methods for diagnosing HBV and agents useful in diagnostic protocols. The present invention further contemplates methods for monitoring disease states in humans and other animal species, including animal models, and providing an indication of the subject for infection by HBV, or development of other diseased states.Type: ApplicationFiled: September 16, 2009Publication date: January 7, 2010Applicants: MELBOURNE HEALTH, MURDOCH CHILDRENS RESEARCH INSTITUTEInventors: Stephen LOCARNINI, Kumar VISVANATHAN
-
Publication number: 20080274083Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: ApplicationFiled: October 20, 2006Publication date: November 6, 2008Applicants: Melbourne Health, Austin HealthInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Peter William Angus
-
Publication number: 20080176218Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.Type: ApplicationFiled: October 31, 2007Publication date: July 24, 2008Applicants: Melbourne Health, St. Vincent's Hospital (Melbourne) Ltd. trading as St. Vincent's Hospital Melbourne, Austin HealthInventors: Angeline Ingrid Bartholomeusz, Stephen Locarnini, Anna Ayres, Margaret Littlejohn, Paul Desmond, Peter William Angus
-
Publication number: 20080171313Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants.Type: ApplicationFiled: October 5, 2007Publication date: July 17, 2008Applicant: MELBOURNE HEALTHInventors: Angeline Bartholomeusz, Margaert Littlejohn, Anna Ayres, Stephen Locarnini
-
Publication number: 20070264284Abstract: The present invention provides regulation of expression of toll-like receptors by the hepatitis B (HBV) pre-core protein, or its extracellular expression product the hepatitis B E antigen (HbeAg). Compounds regulating such expression have use in the treatment and prophylaxis of HBV infection in animal. The invention also provides methods for diagnosing HBV and agents useful in diagnostic protocols. The present invention further contemplates methods for monitoring disease states in humans and other animal species, including animal models, and providing an indication of the subject for infection by HBV, or development of other diseased states.Type: ApplicationFiled: May 19, 2005Publication date: November 15, 2007Inventors: Stephen Locarnini, Kumar Visvanathan
-
Patent number: RE40233Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes.Type: GrantFiled: August 18, 2004Date of Patent: April 8, 2008Assignee: Melbourne HealthInventors: Stephen A Locarnini, Angeline I Bartholomeusz, Thein T. Aye, Robert A. de Man